On the use of molecular biology data in occupational and environmental epidemiology

Journal of Occupational and Environmental Medicine

Volumn 37, Issue 1, 1995, Pages 84-90

  S Ӧ Derkvist, Peter ^a   Axelson, Olav ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOGENOUS COMPOUND;

DATA ANALYSIS; DNA ADDUCT; ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGY; HUMAN; MOLECULAR BIOLOGY; OCCUPATIONAL EXPOSURE; REVIEW;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DNA ADDUCTS; ENVIRONMENTAL HEALTH; EPIDEMIOLOGY, MOLECULAR; HUMAN; OCCUPATIONAL HEALTH; SUPPORT, NON-U.S. GOV'T;

EID: 0028952597     PISSN: 10762752     EISSN: 15365948     Source Type: Journal    
DOI: 10.1097/00043764-199501000-00012     Document Type: Article

References (36)

1. Hemminki K. Use of molecular biology techniques in cancer epidemiology. Scand J Work Environ Health. 1992; 18(Suppl l):38-45.
2. Vineis P. Uses of biochemical and biological markers in occupational epidemiology. Rev Epidemiol Sante Publique. 1992;40:S63-S69.
3. Axelson O, Sӧderkvist P. Characteristics of disease and some exposure considerations. Appl Occup Environ Hygiene. 1991;6:428-435.
4. Lower GM, Nilsson T, Nelson CE, Wolf H, Gamsky TE, Bryan GT. N-Acetyl-transferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ Health Perspect. 1979;29:71-79.
5. Perera FP, Weinstein IB. Molecular epidemiology and carcinogen-DNA adduct detection: new approaches to studies of human cancer causation. J Chron Dis. 1982;35:581-600.
6. Perera FP. Molecular cancer epidemiology: a new tool in cancer prevention. J Natl Cancer Inst. 1982;78:887-98.
7. Indulski JA, Lutz W. Biological monitoring of risk of bladder cancer in persons occupationally exposed to aromatic amines. Pol J Occup Med Environ Health. 1992;5:143-151.
8. Bartsch H, Kadlubar F, O’Neill, eds. Biomarkers in human cancer. Part II. Exposure monitoring and molecular dosimetry. Environ Health Perspect. 1993;99:2-309.
9. Tagesson C, Källberg M, Leanderson P. Determination of urinary 8-hydroxy-deoxyguanosine by coupled-column high-performance liquid chromatography with electrochemical detection: a noninvasive assay for in vivo oxidative DNA damage in humans. Toxicol Methods. 1992;1:242-251.
10. Tagesson C, Chabiuk D, Axelson O, Bar-anski B, Palus J, Wyszynska K. Increased urinary excretion of the oxidative DNA adduct, 8-hydroxy-deoxyguanosine, as a possible early indicator of occupational cancer hazards in the asbestos, rubber, and azo-dye industry. Pol J Occup Environ Health. 1994;6:357-368.
11. Loft S. Metronidazole and antipyrine as probes for a study of foreign compound metabolism. Pharmacol Toxicol 1990; 66(Suppl VI): 1-31.
12. Ayesh R, Idle JR, Ritchie JC, Crothers MJ, Hetzel MR. Metabolic oxidation phenotypes as markers of susceptibility to lung cancer. Nature 1984;312:169-170.
13. Caporaso N, Hayes RB, Dosemeci M, Hoover R, Ayesh R, Hetzel M, Idle J. Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype. Cancer Res. 1989;49:3675-3679.
14. Hanke J, Krajewska B. The biochemical indices of genetic susceptibility to cancer. Acetylation phenotype and bladder cancer. Pol J Occup Med. 1988; 1:306-311.
15. Bock KW. Metabolic polymorphisms affecting activation of toxic and mutagenic arylamines. Trends Pharmacol Sci. 1992; 13:223-226.
16. Wei Q, Matanoski GM, Farmer ER, Hedayati MA, Grossman L. DNA-repair and aging in basal cell carcinoma: A molecular epidemiology study. Proc Natl Acad Sci USA. 1993;90:1614-1618.
17. Gunnarsson L-G, Bodin L, Sӧderfeldt B, Axelson O. A case-control study of motor neurone disease: its relation to heritability, and occupational exposures, particularly to solvents. Br J Ind Med. 1992;49:791-798.
18. Smith CAD, Gough AC, Leigh PN, Leigh PN, Summers BA, Harding AE, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson’s disease. Lancet 1992;339:1375-1377.
19. Balmain A, Brown K. Oncogene activation in chemical carcinogenesis. Adv Cancer Res. 1988;51:147-182.
20. Quintanilla M, Brown K, Ramsden M, Balmain A. Carcinogen specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature. 1986;322:78-80.
21. Zarbl M, Sukumar S, Arthur AV, Martin-Zanca, Barbacid M. Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-A-methylurea during initiation of mammary carcinogenesis in rats. Nature. 1985;315:382-385.
22. Vainio H, Husgafvel-Pursiainen K, Ant-tila S, Karjalainen A, Hackman P, Partanen T. Interaction between smoking and asbestos in human lung adenocarcinoma: role of K-ras muattions. Environ Health Perspect. 1993; 101:189-192.
23. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991;350:429-431.
24. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 1991; 350:427-428.
25. Harris CC, Hollstein M. Clinical implications of the p53 tumor suppressor gene. N Engl J Med. 1993;329:1318-1327.
26. Foster PL, Eisenstadt E, Miller JH. Base substitution mutations induced by metabolically activated aflatoxin Bl. Proc Natl Acad Sci USA. 1983;80:2695-2698.
27. Aguilar F, Hussain SP, Cerutti P. Aflatoxin B1 induces the transversion of G→ T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci. 1993;90:8586-8590.
28. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA. 1991;88:10124-10128.
29. Ziegler AM, Leffell DJ, Kunala S, Sharma HW, Gailani M, Simon JA, Hal-perin AJ, Baden HP, Shapiro PE, Bale AE, Brash DE. Mutation hotspots due to sunlight in the p53 gene of non-melanoma skin cancers. Proc Natl Acad Sci USA. 993;90:4216-4220.
30. Nakazawa H, English D, Randell PL, et al. UV and skin cancer: specific p53 mutation in normal skin as a biologically relevant exposure measurement. Proc Natl Acad Sci USA. 1994;91:360-364.
31. Taylor JA, Sandler DP, Bloomfield CD, Shore DL, Ball ED, Neubauer A, et al. ras oncogene activation and occupational exposures in acute myeloid leukemia. J Natl Cancer Inst. 1992; 84:1626-1632.
32. Vähäkangas KH, Samet JM, Metcalf RA, Welsh JA, Bennett WP, Lane DP, Harris CC. Mutations of p53 and rasgenes in radon-associated lung cancer from uranium miners. Lancet. 1992; 339:576-80.
33. Taylor JA, Watson MA, Devereux TR, Michels RY, Saccomanno G, Anderson M. p53 mutation hotspot in radon-associated lung cancer. Lancet. 1994;343:86-87.
34. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B. 1972;34:187-220.
35. Lee J, Chia KS. Estimation of prevalence rate ratios for cross sectional data: an example in occupational epidemiology. Br J Ind Med. 1993;50:861-862.
36. Axelson O, Fredriksson M, Ekberg K. On the use of the prevalence ratio versus the prevalence odds ratio as a measure of risk in cross-sectional studies. Occup Environ Med 1994;51:574.